Long track record of covering India and @narendramodi eh ? Let's look at the past 4 Climate Transparency Reports since Paris 2016, to confirm your tracking capability:
Table of G20 members and their alignment with Paris NDCs:
4/
Not looking good for your reporting skills. @business is American. The US lists as critically insufficient.
Business mags are read by businessmen. They depend on accurate data being presented. Failing that, the magazine has no value beyond tabloid journalism.
5/
@business You're simply a reporter. You do not define the metrics here. Metrics are in the CTRs, or in CCPI 2021: germanwatch.org/en/19552
6/
What you're doing is point to your prior article as evidence. All that proves is that you agree with yourself.
You're a reporter - report the data - CTR, CCPI. Links are right up here.
Writing alarmist puff pieces and then saying you agree with yourself is silly.
7/7
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Your argument confuses different things - a statement on a commitment, with raw data. The right relationship is the one between the talking and the walking the talk.
How many of the G20 are in line with their Paris NDCs ? Just ONE - India.
To quote a movie dialogue, your egos writing checks your country can’t cash.
2/
Literally the entirety of your argument is that the 3rd biggest economy (PPP terms) is the third biggest emitter. This is as insightful as arguing that water is wet.
Homilies about big emitters having do ‘do something’ are useless virtue signaling noise.
3/
This thread celebrates the occasion of UPI transaction value crossing the $100 billion a month mark, reaching $103 billion in Oct 2021, up from $87 billion in Sept.
UPI transaction value grew 18% MoM in Oct, aided by a 17% MoM growth in volume.
1/
Trailing 12 month transaction volume is now 34.5 billion . This is by a distance the most of any country in the world, having gained almost 10 billion from the FY 2020-21 end volume: dazeinfo.com/2021/05/11/rea…
The slope of this graph is going parabolic:
2/
Trailing 12-month transaction value is currently $852 billion, on track to cross $1 trillion before fiscal year end in March 2022.
The value graph is also accelerating now, and in fact Covid was an inflection point from where UPI has accelerated in adoption and use.
Resuming regular reporting for last week of Oct. Since Dussehra, vaccination has been mostly unremarkable, except that almost every day sees more 2nd doses than first now. This week still sits within the top 10 weeks:
October should end a shade under 180 million doses, around the same ballpark as August, despite 1.5 weeks of the Dussehra festivities.
Data below is up to Oct 30th, i.e. one more day remaining in the month.
2/
While October seems slower, it has been in fact accounted for more weeks in the top 10 than Aug, though the first wk is mostly driven by the ending days of September.
The holiday interregnum may account for perhaps 30-40 million delayed doses; full month is still ~6m/day.
This week’s update will only briefly cover performance - weekly total likely to be ~42 million, same as late Aug/early Sep rate after 1.5 weeks of festival driven slowdown.
The main topic this week is a numerical dive into the 1 billion doses administered performance.
This is of course just the doses administered within India. Total production is approximately 1.25 billion, including supplies sitting with states, exports and wastage.
Covishield exceeds 1 billion doses produced.
Covaxin exceeds European Moderna output, close to US.
2/
Approx 6 billion doses of COVID-19 vaccines have been produced worldwide. 6 entities account for almost all of it: China, India, EU, US, UK and Russia.
India’s peers are lower middle income countries. But it ranks #2 in vaccine output.
This week, the daily bucket chart also highlights weekday public holidays that affect footfalls:
Eid Jul 21
Janmashtami Aug 30
Ganesh Chaturthi Sep 10
Navratri Oct 7-15
Lesser/regional holidays have been skipped only due to lack of pan-India data impact.
2/
The vaccine availability chart shows anomalous behavior this month - rather than a seesaw between supply and use, it has risen until 10th.
Oct started with 50m doses, supply rose to 85m, while consumption was 42.5m -> 77.5m doses supplied, or likely ~265m for the month.
Updating for the start of October. The prior week had 49 million doses. A soft period coming on the back of successive weeks of high performance dominating the top 5 in this chart:
The primary reason for this is a softness in supply coming on the back of 4 long weeks of high performance. However this is now improving as the graph shows, with the available supply back over 50M :
2/
Weekly performance remained steady with no major movement. Trailing 7DMA is now a shade under 7M/day but should go up soon.
I may stop presenting this chart. Oct is likely to have many days over 10M, which this doesn’t show well. If you like this data, please say so.